MedTrace Logo

Adherence to ASV Therapy in Heart Failure With Preserved Ejection Fraction Feasibility Study

NCT03195660 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2021-05-14

Study results available
· View outcomes & findings →

Summary

This study is designed to demonstrate feasibility of study conduct and that acceptable adherence to adaptive servo-ventilation (ASV) therapy can be achieved in recently hospitalized HFpEF patients with moderate to severe sleep apnea. All subjects meeting the criteria will receive ASV therapy.

Conditions

  • Heart Failure With Normal Ejection Fraction
  • Sleep Apnea

Interventions

DEVICE

ASV Therapy

AirCurve 10 ASV device set up in AutoSet mode

Sponsors & Collaborators

  • ResMed

    lead INDUSTRY

Principal Investigators

  • Christopher O'Connor, MD · Inova Heart and Vascular Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-26
Primary Completion
2017-11-15
Completion
2017-11-15
FDA Device
Yes

Countries

  • United States
  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03195660 on ClinicalTrials.gov